Leadership Overview
ImmunityBio has 4 executives leading key functions including strategy, technology, communications, and medical affairs.
Driven by a commitment to innovation, ImmunityBio develops next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases, aiming for durable and safe protection.
Driven by a commitment to innovation, ImmunityBio develops next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases, aiming for durable and safe protection.
Leadership Roles at ImmunityBio
Frank Jones - Chairman & Chief Executive Officer
Frank Jones, the Chairman & Chief Executive Officer at ImmunityBio, directs the overarching strategy and operational execution for the company's development of next-generation therapies and vaccines. This leadership role involves guiding the organization's mission to bolster the natural immune system for combating cancers and infectious diseases. Frank Jones oversees the integration of immunotherapy and cell therapy platforms, ensuring their combined action drives and sustains immune responses for durable disease protection. The Chairman & Chief Executive Officer is responsible for advancing the company's pipeline, including ANKTIVA, the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS, and other potential cancer vaccines. This executive ensures the scientific and business strategies align with the goal of creating more effective, accessible, and easily administered treatments than current standards of care in oncology and infectious diseases, thereby shaping the future of patient care.
Enrique Diloné - Chief Technology Officer
Enrique Diloné, the Chief Technology Officer at ImmunityBio, architects the technological infrastructure and innovation pipeline for the company's groundbreaking therapies and vaccines. This executive spearheads the advancement of immunotherapy and cell therapy platforms, ensuring their seamless integration and optimal performance in bolstering the natural immune system. Enrique Diloné drives the research and development efforts focused on creating durable and safe protection against cancers and infectious diseases. The Chief Technology Officer oversees the technical aspects of developing next-generation treatments, including potential cancer vaccines and immunotherapies designed to reduce or eliminate the need for high-dose chemotherapy. By focusing on accessibility and ease of administration, this leadership role ensures ImmunityBio's technological solutions meet and exceed current standards of care, positioning the company at the forefront of biotechnological advancement in oncology and infectious disease treatment.
Sarah Singleton - Chief Communications Officer & Head of Patient Advocacy
Sarah Singleton, the Chief Communications Officer & Head of Patient Advocacy at ImmunityBio, shapes and disseminates the company's narrative, ensuring clear communication of its mission and scientific advancements. This executive leads external and internal communications strategies, highlighting ImmunityBio's commitment to developing next-generation therapies and vaccines that enhance the natural immune system. Sarah Singleton champions patient advocacy, fostering strong relationships with patient communities and ensuring their perspectives inform the company's development of treatments for cancers and infectious diseases. The Chief Communications Officer & Head of Patient Advocacy oversees the messaging around groundbreaking products like ANKTIVA, emphasizing their role in creating durable and safe protection. This leadership position ensures that the accessibility and efficacy of ImmunityBio's innovative platforms are effectively communicated to stakeholders, including healthcare professionals, investors, and the public, reinforcing the company's impact on patient lives.
Leonard Sender - Chief Medical Officer, Liquid Tumors & Cell Therapy
Leonard Sender, the Chief Medical Officer, Liquid Tumors & Cell Therapy at ImmunityBio, directs clinical development strategies for novel immunotherapies and cell therapies targeting liquid tumors. This executive oversees the clinical trial design and execution, focusing on harnessing the natural immune system to combat these challenging diseases. Leonard Sender's leadership is critical in advancing the company's pipeline, including the development of potential cancer vaccines and cell-based treatments aimed at providing durable and safe protection. The Chief Medical Officer, Liquid Tumors & Cell Therapy ensures that clinical programs align with the company's goal of creating more effective and accessible treatments, potentially reducing the need for traditional chemotherapy. This role involves close collaboration with regulatory bodies, including the FDA, to expedite the approval process for groundbreaking therapies like ANKTIVA, thereby driving significant advancements in oncology care.
Explore Leadership Teams in Manufacturing
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company Leadership ES
SS
BH
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a fully integrated global essential medicines company powered by a robust U.S. generics business and a growing branded business as well as deepening portfolios in institutional injectables, biosimilars and select international markets. Together, were rapidly becoming one of the most dynamic, purpose-driven pharmaceutical companies delivering more affordable access to essential medicines. Today, Amneal is much more than generics. A series of strategic investments over the years has bolstered our world-class scientific rigor, production capabilities and commercial infrastructure. We have also invested substantially in our people through leadership development and employee well-being programs. Together, these advancements have accelerated our ability to deliver innovation, more complex products and broadened portfolios in new categories and geographies. Two decades after our founding, Amneal is better positioned than ever to deliver outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrows health challenges. We are Amneal and We make healthy possible.
Company Leadership
HK
Established in 1978 and headquartered in London, Hikma Pharmaceuticals is a multinational pharmaceutical company that manufactures branded and non-branded generic and in-licensed pharmaceutical products.
Company Leadership
TD
CS
Jamjoom Pharma is one of the leading pharmaceutical companies in the Afrasia region focused on the Middle East, Africa, and CIS countries. Based in Jeddah, Saudi Arabia, Jamjoom Pharma manufactures and markets pharmaceutical products, over the counter (OTC) medicines, and health related consumer products. The company is owned by the Jamjoom Group.
Company Leadership NS
TH
AM
AH
Frequently Asked Questions Regarding ImmunityBio Top Executives and Leadership Team
Unlock more people and company data
